Navigating treatment approaches for presumed ESBL-producing infections

Pranita D. Tamma, Amy J. Mathers

Research output: Contribution to journalArticlepeer-review


ESBL-producing Enterobacterales (ESBL-E) remain a significant global threat. In several regions of the world, ESBLs are produced by over half of Escherichia coli or Klebsiella pneumoniae infections, contributing to significant morbidity and mortality. Though it is accepted that carbapenems are effective for the treatment of invasive ESBL-E infections, controversy remains as to whether carbapenem alternatives can be considered in select cases. Indiscriminate carbapenem use for the treatment of ESBL-E infections will likely further the international antimicrobial resistance crisis, underscoring the importance of investigating the role of non-carbapenem options. In this issue of JAC-Antimicrobial Resistance, we present a PRO/CON debate exploring whether carbapenems are necessary for all infections caused by ceftriaxone-resistant Enterobacterales.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalJAC-Antimicrobial Resistance
Issue number1
StatePublished - Mar 1 2021

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Immunology
  • Microbiology
  • Immunology and Allergy


Dive into the research topics of 'Navigating treatment approaches for presumed ESBL-producing infections'. Together they form a unique fingerprint.

Cite this